Kite taps Adimab to lend a hand in CAR-T R&D

Kite Pharma ($KITE), at work on therapies that use the immune system to fight cancer, paired up with Adimab to expand its R&D efforts. Under the partnership, Adimab will generate antibodies against some Kite-selected targets, and the latter company will have the exclusive right to license them for use in its development of CAR-T therapies. Neither side is disclosing financial details of the agreement. Kite, devoted to treatments that rewire human T cells, joins a long list of companies that have looked to Adimab for antibody creation. The biotech has signed more than 30 such licensing deals in recent years, with a roster of partners that includes Sanofi ($SNY), Merck ($MRK), Roche ($RHHBY), Novartis ($NVS), Eli Lilly ($LLY) and GlaxoSmithKline ($GSK). News

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.